Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | BCR | P11274 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198863 | 0.88 | HSD11B1 (0.81) | HSD11B1GBA1NAMPT | |
| SCHEMBL3223804 | 0.86 | HSD11B1 (0.79) | HSD11B1ABL1BCRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3217790 | 0.86 | HSD11B1 (1.00) | HSD11B1ABL1BCRGBA1 | |
| SCHEMBL3224382 | 0.83 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3212746 | 0.82 | HSD11B1 (0.76) | HSD11B1GBA1 | |
| SCHEMBL3222011 | 0.82 | HSD11B1 (0.76) | HSD11B1SMN1; SMN2ALDH1A1TSHRGBA1 | |
| SCHEMBL3210941 | 0.82 | HSD11B1 (0.72) | HSD11B1ABL1BCRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3218052 | 0.81 | HSD11B1 (0.66) | HSD11B1ALDH1A1GAAGBA1 | |
| SCHEMBL1974783 | 0.78 | ALDH1A1 (0.85) | HSD11B1SMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL3217991 | 0.77 | HSD11B1 (0.81) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885ABL1 4341/4885BCR 4136/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885ABL1 4095/4885BCR 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.